Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT – BOTHELL, WA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),...
-
BOTHELL, WA, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
-
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
-
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
-
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviralagents progresses – ...
-
– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus...
-
- Company has sufficient capital to advance pipeline and fund operations through 2021 - BOTHELL, WA, May 14, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the...
-
– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program – – Discussions ongoing with potential strategic...
-
- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program - - Small molecule therapeutic inhibitors against coronaviruses included in agreement have...
-
- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals - ...